Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology
Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder cancer population undergoing instillations
Study conducted at Agostino Gemelli University Hospital in Rome, Italy, shows it would be safe and effective to use Bladder EpiCheck to avoid unnecessary cystoscopies in high-risk patients.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.